{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT05740943","nct_id":"NCT05740943","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05740943. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients will receive 12-week induction Lorlatinib followed by radical surgery or local radiotherapy or continue Lorlatinib through MDT and optional consolidation lorlatinib for up to 2 years.","label":"Treatment Arm","type":"EXPERIMENTAL"}],"collaborators":["Guangzhou No.12 People's Hospital","Peking Union Medical College Hospital","Second Xiangya Hospital of Central South University"],"completion_date":{"date":"2026-04-30","type":"ESTIMATED"},"conditions":["Stage III NSCLC","Surgery"],"enrollment":{"count":48,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Lorlatinib","type":"DRUG"}],"last_update":"2026-01-20","lead_sponsor":"Guangdong Provincial People's Hospital","official_title":"Induction Lorlatinib for ALK Fusion Locally Advanced Non-small Cell Lung Cancer: A Prospective, Single Arm, Open-label Phase 2 Study","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-12-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Pathological Complete Response (pCR)","timeFrame":"After surgery (approximately 2 weeks)"}],"references":[{"citation":"Zhang C, Li SL, Nie Q, Dong S, Shao Y, Yang XN, Wu YL, Yang Y, Zhong WZ. Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement. J Thorac Oncol. 2019 Apr;14(4):726-731. doi: 10.1016/j.jtho.2018.10.161. Epub 2018 Nov 5.","pmid":"30408570","type":"BACKGROUND"},{"citation":"Leonetti A, Minari R, Boni L, Gnetti L, Verze M, Ventura L, Musini L, Tognetto M, Tiseo M. Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial. Clin Lung Cancer. 2021 Sep;22(5):473-477. doi: 10.1016/j.cllc.2021.02.014. Epub 2021 Feb 24.","pmid":"33762169","type":"BACKGROUND"},{"citation":"Zhang C, Yan LX, Jiang BY, Wu YL, Zhong WZ. Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC. J Thorac Oncol. 2020 Jun;15(6):e95-e99. doi: 10.1016/j.jtho.2019.12.133. No abstract available.","pmid":"32471573","type":"BACKGROUND"},{"citation":"Chaft JE, Dagogo-Jack I, Santini FC, Eng J, Yeap BY, Izar B, Chin E, Jones DR, Kris MG, Shaw AT, Gainor JF. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer. 2018 Aug;122:67-71. doi: 10.1016/j.lungcan.2018.05.020. Epub 2018 May 22.","pmid":"30032847","type":"BACKGROUND"},{"citation":"Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187.","pmid":"33207094","type":"BACKGROUND"}],"start_date":{"date":"2023-03-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Induction Lorlatinib in Stage III Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05740943"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05740943"}